Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.

Cancer research and treatment - 1 Apr 2021

Lin Lin, Cai Jinquan, Tan Zixiao, Meng Xiangqi, Li Ruiyan, Li Yang, Jiang Chuanlu

Abstract excerpt

PURPOSE: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. MATERIALS AND METHODS: IDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Temozolomide

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33070553
DOI: 10.4143/crt.2020.506
PMCID: PMC8053882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.PMID 33070553Read ↗

IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.Semantic proximity Read ↗

IDH1 <sup>R132H</sup> acts as a tumor suppressor in glioma via epigenetic upregulation of the DNA damage responseSemantic proximity Read ↗

Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.Semantic proximity Read ↗

IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.Semantic proximity Read ↗

Tumor Mutational Burden Predicts Survival In Patients With Low Grade Gliomas Expressing Mutated IDH1Semantic proximity Read ↗

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.Semantic proximity Read ↗

IDH1 mutation diminishes aggressive phenotype in glioma stem cells.Semantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.Semantic proximity Read ↗

IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage responseSemantic proximity Read ↗

Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.Semantic proximity Read ↗

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.